Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04840771
Other study ID # 04/21
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2020
Est. completion date July 31, 2020

Study information

Verified date May 2021
Source Federico II University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the structural parameters, by spectral domain optical coherence tomography (OCT), retinal vessel density, using OCT angiography, and visual acuity in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.


Description:

The primary outcome was to detect the changes in visual acuity, retinal structural and vascular features at 48 hours and 1 year after Endoscopic Endonasal Approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve. The secondary outcome was to identify potential biomarker that could predict the functional recovery at 1 year follow up.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date July 31, 2020
Est. primary completion date July 30, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: - age older than 40 years - diagnosis of pituitary adenoma - treatment-naïve with Endoscopic Endonasal Pituitary Surgery - absence of other neurological diseases - absence of vitreoretinal and vascular retinal diseases Exclusion Criteria: - age younger than 40 years - No diagnosis of pituitary adenoma - previous treatments with Endoscopic Endonasal Pituitary Surgery - presence of neurological diseases - presence of vitreoretinal and vascular retinal diseases

Study Design


Intervention

Procedure:
Endoscopic Endonasal Pituitary Surgery
Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.

Locations

Country Name City State
Italy University of Naples "Federico II" Naples

Sponsors (1)

Lead Sponsor Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison between retinal structures before and 48 hours and 1 year after Endoscopic Endonasal Pituitary Surgery 8 patients with pituitary adenoma compressing optic chiasm. Changes in thickness of ganglion cell complex (microns) and in thickness of retinal nerve fiber layer (microns) before and 48 hours and 1 year after Endoscopic Endonasal Pituitary Surgery 48 hours and 1 year follow up
Primary Comparison between retinal microvasculature before and 48 hours and 1 year after Endoscopic Endonasal Pituitary Surgery 8 patients with pituitary adenoma compressing optic chiasm. Changes in retinal vessel density (percent) in macular and papillary regions before and 48 hours and 1 year after Endoscopic Endonasal Pituitary Surgery 48 hours and 1 year follow up
Secondary Correlation between retinal structures and visual acuity after Endoscopic Endonasal Pituitary Surgery 8 patients with pituitary adenoma compressing optic chiasm underwent Endoscopic Endonasal Pituitary Surgery.
Correlation between ganglion cell complex, retinal nerve fiber layer thicknesses (microns) at baseline and visual acuity recovery (logMAR) 1 year after surgery.
1 year follow up
Secondary Correlation between retinal microvasculature and visual acuity after Endoscopic Endonasal Pituitary Surgery 8 patients with pituitary adenoma compressing optic chiasm underwent Endoscopic Endonasal Pituitary Surgery.
Correlation between retinal vessel density (percent) at baseline and visual acuity recovery (logMAR) 1 year after surgery.
1 year follow up
See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Completed NCT01689064 - Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection N/A
Recruiting NCT04611685 - Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas N/A
Completed NCT04212793 - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW Phase 1
Recruiting NCT02709863 - Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests N/A
Completed NCT01465672 - Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis N/A
Terminated NCT00798057 - Proton Radiation Therapy for Pituitary Adenoma N/A
Completed NCT01504399 - Rhinological Outcomes in Endonasal Pituitary Surgery
Recruiting NCT01556230 - Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Completed NCT04074642 - OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study. N/A
Recruiting NCT04621565 - Hydrocortisone Use During Peri-operation for Pituitary Adenomas N/A
Completed NCT04076046 - Multicentric Prospective Validation of the Zurich Pituitary Score
Not yet recruiting NCT03714763 - Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA) N/A
Not yet recruiting NCT04569591 - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease N/A
Recruiting NCT05822817 - Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery Phase 4
Recruiting NCT03164148 - Heart Rate Variability (HRV) in Pituitary Adenoma N/A
Completed NCT04284605 - Effects Exercise Training in Patients With Pituitary Adenoma N/A
Terminated NCT03515603 - Endocrine Outcome of Surgery for Pituitary Adenoma N/A
Not yet recruiting NCT04863456 - Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement N/A
Active, not recruiting NCT03465618 - A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors Phase 1